Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’
BioSpace
Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.
pharminent
April 28, 2026 (Last updated: April 28, 2026)
BioSpace
Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.